Comparing the current results to its competitors, Monopar Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 17.5 %, recorded in the same quarter.
Monopar Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 2.34 %
October 15, 2024
In a significant move that could reshape the landscape of cancer treatment, Monopar Therapeutics Inc. (Nasdaq: MNPR) has announced the filing of a provisional patent that expands its portfolio of radiopharmaceutical intellectual property. This strategic initiative, unveiled on October 15, 2024, is focused on new therapeutic radiopharmaceuticals based on a novel family of linkers designed to connect radioisotopes with targeting agents, notably the company’s uPAR-targeting antibody, MNPR-101. Exploring the DetailsMonopar Therapeutics, based in Wilmette, Illinois, is a clinical-stage company dedicated to developing groundbreaking treatments for cancer patients. The newly filed provisional patent underlines it...
September 12, 2024
In the illustrious annals of medical advancement, it is with unbridled optimism that we turn our attention to the recent pronouncement by Monopar Therapeutics Inc. a beacon of innovation within the domain of clinical-stage radiopharmaceutical enterprises. On the twelfth day of September in the year of our Lord, two thousand twenty-four, this esteemed company divulged the auspicious findings of its ongoing open-label clinical trial, designated as MNPR-101-Zr Phase 1, which sought to elucidate the profound efficacy of MNPR-101-Zr in targeting tumorous formations within the human body.In a time when the spectre of cancer looms large over the collective consciousness of society, the quest for pioneering therapeu...
On August 21, 2024, Monopar announced a significant milestone: the Human Research Ethics Committee (HREC) in Australia granted clearance to initiate a Phase 1 therapeutic trial for MNPR-101-Lu in patients with advanced cancers. This novel radiopharmaceutical combines Monopar's proprietary antibody MNPR-101, which targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177 (Lu-177). This development underscores Monopar’s commitment to advancing cancer treatment through precision medicine.
The Phase 1 trial aims to evaluate the safety, tolerability, and initial efficacy of MNPR-101-Lu in humans. Given the innovative mechanism of action, whereby the antibody selectively binds to uPAR a receptor abundantly expressed in various aggressive tumors MNPR-101-Lu holds significant potential to selectively deliver the radioactive payload to tumor cells, minimizing collateral damage to healthy tissues. First Patient Enrolled in the Phase 1 Dosimetry and Imaging Trial of MNPR-101-Zr
Following the HREC clearance, Monopar's momentum continued with another landmark achievement. On July 9, 2024, the company announced the enrollment of the first patient in its first-in-human Phase 1 dosimetry and imaging clinical trial of MNPR-101-Zr. This novel imaging agent is a combination of Monopar's MNPR-101 antibody and the radioisotope zirconium-89 (Zr-89).
The primary of this trial is to understand the dosimetry and biodistribution of MNPR-101-Zr in patients, hence providing crucial insights into the optimal dosing strategies and therapeutic potential of the antibody. Imaging with Zr-89 allows researchers to visualize and track the distribution of MNPR-101 within the body using positron emission tomography (PET). This information will guide the subsequent development stages of therapeutic versions of MNPR-101, such as MNPR-101-Lu. Global Recognition at EANM 2024
Monopar’s innovative research has not gone unnoticed in the scientific community. On June 25, 2024, it was announced that an abstract
August 21, 2024
Radiopharmaceutical Revolution: Monopar Therapeutics Multi-Faceted Approach in Targeting Advanced Cancers Monopar Therapeutics Inc. (Nasdaq: MNPR), a pioneering clinical-stage radiopharmaceutical company, has embarked on an exciting journey to bring innovative treatments to cancer patients. The company is making waves with its novel radiopharmaceuticals, MNPR-101-Lu and MNPR-101-Zr, designed to revolutionize cancer therapy and diagnostic imaging. This article delves into Monopar s recent advancements, emphasizing the clearance for a Phase 1 therapeutic trial of MNPR-101-Lu, the first-in-human Phase 1 trial enrollment for MNPR-101-Zr, and the recognition of their work at the upcoming European Association of...
July 9, 2024
WILMETTE, Ill., July 09, 2024 - Monopar Therapeutics Inc. (Nasdaq: MNPR), an innovative clinical-stage radiopharmaceutical company dedicated to advancing cancer treatments, proudly announces the enrollment of its first patient in the groundbreaking Phase 1 dosimetry and imaging clinical trial for MNPR-101-Zr. This novel radiopharmaceutical imaging agent harmoniously combines Monopar s antibody, MNPR-101, designed to selectively target the urokinase plasminogen activator receptor (uPAR), with the powerful radioisotope zirconium-89.In a bold step towards revolutionizing the field of cancer therapy, Monopar s MNPR-101-Zr offers renewed hope to cancer patients seeking effective and precision-guided treatment. Th...
February 27, 2024
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in developing innovative cancer treatments, has announced the appointment of renowned radiopharmaceutical physician Professor Rodney Hicks as the lead investigator for the MNPR-101-Zr Phase 1 dosimetry clinical trial. This significant development aims to evaluate the targeting ability of MNPR-101-Zr in treating advanced cancer patients. Professor Hicks will conduct the trial at the Melbourne Theranostic Innovation Centre (MTIC) using state-of-the-art imaging technology.Key Facts:1. Monopar Therapeutics Inc. has appointed Professor Rodney Hicks as the lead investigator for the MNPR-101-Zr Phase 1 dosimetry clinical trial.2. The...
February 20, 2024
Monopar Therapeutics Begins First-in-Human Phase 1 Trial of Innovative Radiopharmaceutical MNPR-101-Zr in Advanced CancersIn a groundbreaking development for cancer treatment, Monopar Therapeutics Inc. has recently obtained clearance from the Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1 dosimetry trial for its novel radiopharmaceutical, MNPR-101-Zr. This milestone marks a significant step forward in the company s pursuit of innovative treatments for advanced cancers.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing cutting-edge therapies for cancer patients, is focused on harnessing the power of radiopharmaceuticals to revolutionize can...
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Sources:
Monopar Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Monopar Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
